Psyence Expands Scientific Expertise with New Appointment
Psyence Group Inc (CSE: PSYG) is making headlines with its growing network in the field of psychedelic research. With a focus on developing groundbreaking therapeutic solutions, its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM), has recently welcomed Dr. Dan J. Stein to its Scientific Advisory Board (SAB). Dr. Stein is an acclaimed figure in psychopharmacology, known for his significant contributions to understanding mental health disorders.
Dr. Dan J. Stein's Renowned Background
Dr. Stein serves as the Professor and Chair of the Department of Psychiatry and Mental Health at the University of Cape Town and leads the South African Medical Research Council Unit on Risk & Resilience in Mental Disorders. His involvement is expected to bolster the direction and vision of PBM's scientific endeavors. Collaborating closely with the SAB chairman, Albert P. Garcia-Romeu, Ph.D., a notable Associate Professor at Johns Hopkins University, Dr. Stein’s expertise will guide PBM in its ongoing research initiatives.
Continuing the Psychedelic Research Journey
Psyence Biomedical is advancing its clinical trials, particularly the Phase IIb study focused on using psilocybin as a treatment for Adjustment Disorder in Palliative Care. The announcement of Dr. Stein's addition to the SAB aligns with PBM's plans to expand its therapeutic applications, which now includes a push into Alcohol Use Disorder. This venture marks the introduction of novel psilocybin-based treatments, aiming to fulfill the critical unmet needs in mental health and addiction sectors.
Upcoming Corporate Webinar
In conjunction with this news, PBM has announced it will host a corporate webinar, taking place soon. This event will feature discussions led by the executive team regarding the role of the SAB and PBM’s ambitious roadmap in psychedelic therapeutics. This is a vital opportunity for stakeholders and interested parties to gain insight into PBM’s progress and future strategies.
About Psyence Group and Psyence Biomed
Psyence Group stands out as a pioneering life science biotechnology company listed on the Canadian Securities Exchange, with a significant focus on natural psychedelics. Distinctively, Psyence Biomed is recognized as the world's first psychedelic biotechnology company traded on Nasdaq, developing botanical psilocybin-based medicines aimed at addressing mental health trauma, especially within palliative care settings.
Our Commitment to Science and Nature
The mission behind the name "Psyence" merges the realms of psychedelics and scientific inquiry, representing the dedication of Psyence Group to developing evidence-driven medicinal products. The company relentlessly pursues the creation and refinement of natural psilocybin therapies, driven by the goal of enhancing clinical research and patient outcomes.
Company and Investor Communications
Psyence Group encourages interested individuals to learn more about their innovative approaches by visiting their official website. For any media inquiries or detailed information on the latest developments, the company provides various avenues of communication including designated emails and a direct phone line.
Frequently Asked Questions
What is the primary focus of Psyence Group?
Psyence Group is focused on developing natural psychedelics for therapeutic use, particularly in mental health and addiction treatments.
Who is Dr. Dan J. Stein?
Dr. Dan J. Stein is a prominent figure in psychopharmacology and has recently joined the Scientific Advisory Board of Psyence Biomedical.
What clinical trial is Psyence Biomedical currently running?
Psyence Biomedical is currently engaged in a Phase IIb clinical trial exploring psilocybin as a treatment for Adjustment Disorder in Palliative Care.
How can investors and interested parties learn more about Psyence Biomedical?
Investors and interested individuals can visit the Psyence Group’s website or participate in upcoming corporate webinars for more information.
What role does the Scientific Advisory Board play?
The Scientific Advisory Board provides expertise and guidance for ongoing and future research initiatives, aiming to enhance the development of therapeutic solutions.
